Sulindac

ATC Code M01AB02

Sulindac

Definition

A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04)

Also known as (Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid, Aflodac, Algocetil, Apo-Sulin, Arthrocine, Artribid, cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid, Citireuma, Clinoril, Clisundac, Imbaral, MK-231, Novo-Sundac, Reumofil, Reumyl, Sudac, SULINDAC, Sulindac Sulfoxide, Sulinol, Sulreuma — per NCIT

Also identified as

Indications

Disease Relation Source
Ankylosing spondylitis may treat MEDRT · Public domain (U.S. Government work)
Bursitis may treat MEDRT · Public domain (U.S. Government work)
Disease of the tendon may treat MEDRT · Public domain (U.S. Government work)
Osteoarthritis may treat MEDRT · Public domain (U.S. Government work)
Rheumatoid arthritis may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Bone element may treat a disease of this organ DERIVED · CC BY 4.0
Musculoskeletal system may treat a disease of this organ DERIVED · CC BY 4.0
Skeletal joint may treat a disease of this organ DERIVED · CC BY 4.0

3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.